Whalesbook
Centennial Surgical Suture Flags Suspected Price Manipulation to BSE
Centennial Surgical Suture Ltd. has officially notified the BSE's Investigation/Surveillance Department about significant and alleged manipulative trading activities observed in its stock between February 6 and February 13, 2026. The company asserts that a recent abnormal price surge in its scrip is artificial, unsupported by any material corporate announcements or business developments, and is detrimental to genuine investors. Consequently, it has formally requested an urgent investigation into potential violations of SEBI (Prohibition of Fraudulent and Unfair Trade Practices) Regulations, 2003.
Allegations of Artificial Price Surge and Manipulation
In a detailed letter submitted to the BSE, Centennial Surgical Suture Ltd. outlined its concerns, pointing to trading patterns that do not align with the company's actual financial performance. The company stated that the price rise was "solely on account of the manipulations committed by the group entities." Specific manipulative tactics alleged include:
- Unusual Trading Patterns: The company observed individuals buying and selling very small quantities of shares, such as 1, 2, 3, 4, or 5 shares, which can be indicative of attempts to create artificial activity.
- Trading Above Last Traded Price (LTP): It was noted that some trades were executed at prices higher than the Last Traded Price, potentially to artificially inflate the stock's perceived value.
- Circular Trading: The nature and frequency of certain transactions suggested circular trading, where shares are bought and sold among related parties without a real change in beneficial ownership, thereby creating a false impression of market interest.
- Defeating Market Mechanism: Transactions were allegedly executed with the intent to manipulate the market mechanism for wrongful gains.
The company explicitly mentioned contravention of Regulations 3 (a), (b), (c), and (d), and 4(1), (2), (a), and (e) of the SEBI (Prohibition of Fraudulent and Unfair Trade Practices) Regulations, 2003. These regulations prohibit activities like creating a false or misleading appearance of trading, dealing in securities not to effect ownership transfer but to manipulate prices, and employing schemes to defraud investors.
Financial Performance Amidst Allegations
Centennial Surgical Suture Ltd.'s recent financial reports present a mixed picture. For the third quarter of fiscal year 2026 (ended December 31, 2025), the company reported a net profit of ₹0.15 crores, a significant turnaround from a loss of ₹0.85 crores in the prior year's comparable quarter. Revenue also saw a healthy 21.80% year-on-year increase to ₹14.86 crores [1].
However, deeper analysis reveals underlying financial challenges. The company has a concerning five-year EBIT growth rate of -21.26% [1], [10], [23], indicating a long-term decline in operating profitability. Furthermore, its return on equity (ROE) remains negative at -6.78% [1], [11], [20], [23], suggesting issues with capital efficiency. In fiscal year 2025, the company incurred profit after tax (PAT) losses due to increased depreciation and higher interest costs from increased leverage, leading to a downgrade in its bank facilities' ratings by Crisil to 'BB+/Stable/A4+' [13]. Long-term debt has also more than doubled in the past year [1]. These financial metrics lend credence to the company's claim that the recent stock price surge was "not in synchronisation with the actual financial performance" [1].
Past Concerns and Investor Impact
Previous correspondence with BSE has indicated "unusual trades" and "manipulative intention" in past trading periods [21]. The company's current stance is that it, its promoters, or employees have not traded in shares and it is ready to cooperate with any investigation. The core concern for genuine investors is that such alleged manipulation can lead to significant financial losses, as entities are accused of deriving "huge profits" by manipulating prices while causing losses to others.
Risks and Outlook
The primary risks for investors at this juncture include the potential for continued stock price volatility driven by manipulative activities, SEBI's findings from the investigation, and the company's ability to address its long-standing financial weaknesses. A thorough investigation by SEBI could lead to regulatory actions, including fines or trading restrictions, if violations are confirmed. The company's ability to achieve sustainable profitability and manage its debt load remains a key challenge.
Peer Comparison
Centennial Surgical Suture operates in the Indian surgical sutures and staplers market, a sector projected for substantial growth, driven by increasing surgical procedures and evolving healthcare infrastructure [3], [4], [6]. This market is competitive, featuring major players like Ethicon, Medtronic, B. Braun, and Healthium Medtech [3], [4], [6], [14]. While Centennial Surgical Suture holds a market position [14], it faces intense competition from both domestic and international companies. The market's overall health contrasts with the specific financial pressures faced by Centennial Surgical Suture.